---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-030127"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:42:29.865960+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# MTAC amends term sheet with Magnetar, increasing expense reimbursement cap to $600K

## Summary
- Amendment raises Magnetar's expense reimbursement cap from $300,000 to $600,000 for the proposed $50M convertible note financing.
- Notes are 8.0% senior secured convertible notes concurrent with the TriSalus business combination.
- Financing is contingent on closing of the business combination with TriSalus Life Sciences.

## SEC filing metadata
- accession: 0001104659-23-030127
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/tm238778d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-030127
- JSON: https://secwatch.observer/filing/0001104659-23-030127.json
- Plain text: https://secwatch.observer/filing/0001104659-23-030127.txt

## Key facts
- Material Agreements
  TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation valued at Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm (effective 2022-11-11).
  - Action: entry
  - Agreement: merger
  - Counterparty: MedTech Acquisition Corporation
  - Value: Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm
  - Effective: 2022-11-11
  source text: On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.